Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures

Pediatric Pulmonology

Volumn 45, Issue 6, 2010, Pages 569-577

  Zemanick, Edith T ^a   Wagner, Brandie D ^b   Harris, J Kirk ^a   Wagener, Jeffery S ^a   Accurso, Frank J ^a   Sagel, Scott D ^a  

^a Children's Hospital Colorado   (United States)

^b Global Health and Health Disparities   (United States)

Author keywords

Airway infection; Bronchoalveolar lavage; Lung function; Sputum culture

Indexed keywords

ACINETOBACTER; ACTINOMYCES; ADOLESCENT; AGING; ARTICLE; BACTERIUM CULTURE; BACTERIUM DETECTION; BODY MASS; CHILD; COMPARATIVE STUDY; COUGHING; CYSTIC FIBROSIS; DEMOGRAPHY; DISEASE EXACERBATION; ENTEROBACTER CLOACAE; FATIGUE; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; LEUKOCYTE COUNT; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEUTROPHIL; NOCARDIA; NONHUMAN; OXYGEN SATURATION; POLYMORPHONUCLEAR CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS FLUORESCENS; PSEUDOMONAS MENDOCINA; RALSTONIA; RETROSPECTIVE STUDY; SCHOOL CHILD; SERRATIA MARCESCENS; SPUTUM ANALYSIS; SPUTUM CULTURE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS GROUP A; THROAT CULTURE; VIRUS CULTURE;

ADOLESCENT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BRONCHOALVEOLAR LAVAGE FLUID; CHILD; CYSTIC FIBROSIS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; SPUTUM; TOBRAMYCIN; YOUNG ADULT;

EID: 77953312034     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21221     Document Type: Article

References (44)

1. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918-951.
2. Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax 2007;62:360-367.
3. Amadori A, Antonelli A, Balteri I, Schreiber A, Bugiani M, De Rose V. Recurrent exacerbations affect FEV(1) decline in adult patients with cystic fibrosis. Respir Med 2009;103:407-413.
4. Mayer-Hamblett N, Ramsey BW, Kronmal RA. Advancing outcome measures for the new era of drug development in cystic fibrosis. Proc Am Thorac Soc 2007;4:370-377.
5. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153:345-352.
6. Burns JL, Emerson J, Stapp JR, Yim DL, Krzewinski J, Louden L, Ramsey BW, Clausen CR. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998; 27:158-163. (Pubitemid 28334435)
7. Lambiase A, Raia V, Del Pezzo M, Sepe A, Carnovale V, Rossano F. Microbiology of airway disease in a cohort of patients with cystic fibrosis. BMC Infect Dis 2006;6:4.
8. Ferkol T, Rosenfeld M, Milla CE. Cystic fibrosis pulmonary exacerbations. J Pediatr 2006;148:259-264.
9. Amin R, Dupuis A, Aaron SD, Ratjen F. The effect of chronic infection with aspergillus fumigatus on lung function and hospitalization in cystic fibrosis patients. Chest 2010;137: 171-176.
10. Razvi S, Saiman L. Nontuberculous mycobacteria in cystic fibrosis. Pediatr Infect Dis J 2007;26:263-264.
11. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996;335:179-188.
12. Smyth A, Elborn JS. Exacerbations in cystic fibrosis: 3 - Management. Thorax 2008;63:180-184.
13. Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990;141:914-921.
14. Nixon GM, Armstrong DS, Carzino R, Carlin JB, Olinsky A, Robertson CF, Grimwood K, Wainwright C. Early airway infection, inflammation, and lung function in cystic fibrosis. Arch Dis Child 2002;87:306-311.
15. Petersen NT, Hoiby N, Mordhorst CH, Lind K, Flensborg EW, Bruun B. Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma - Possible synergism with Pseudomonas aeruginosa. Acta Paediatr Scand 1981;70:623-628. (Pubitemid 12196513)
16. Zemanick ET, Harris JK, Wagner BD, Accurso FJ, Sagel SD. Characteristics of cystic fibrosis patients with pulmonary exacerbation and no detectable CF airway pathogens [abstract]. Am J Respir Crit Care Med 2009;179:A1787.
17. Gilligan PH. Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 1991;4:35-51.
18. Zhou J, Garber E, Desai M, Saiman L. Compliance of clinical microbiology laboratories in the United States with current recommendations for processing respiratory tract specimens from patients with cystic fibrosis. J Clin Microbiol 2006;44:1547-1549.
19. Castellani C, Cuppens H, Macek M, Jr., Cassiman JJ, Kerem E, Durie P, Tullis E, Assael BM, Bombieri C, Brown A, Casals T, Claustres M, Cutting GR, Dequeker E, Dodge J, Doull I, Farrell P, Ferec C, Girodon E, Johannesson M, Kerem B, Knowles M, Munck A, Pignatti PF, Radojkovic D, Rizzotti P, Schwarz M, Stuhrmann M, Tzetis M, Zielenski J, Elborn JS. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros 2008;7:179-196.
20. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-187.
21. Wang X, Dockery DW, Wypij D, Gold DR, Speizer FE, Ware JH, Ferris BG, Jr. Pulmonary function growth velocity in children 6 to 18 years of age. Am Rev Respir Dis 1993;148: 1502-1508.
22. Rosenfeld M, Coates A, Corey M, Goss CH, Howard MB, Morgan W, Quinton H, Schluchter M. Task Force to Evaluate Choice of Spirometric Reference Equations for the National Patient Registry: Summary and Recommendations. Cystic Fibrosis Foundation Registry Committee; 1 Oct 2005.
23. Cystic Fibrosis Foundation. Clinical Practice Guidelines for Cystic Fibrosis. Bethesda, MD: Cystic Fibrosis Foundation; 1997.
24. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990;1:43-46.
25. Konstan MW, Morgan WJ, Butler SM, Pasta DJ, Craib ML, Silva SJ, Stokes DC, Wohl ME, Wagener JS, Regelmann WE, Johnson CA. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007;151:134-139.
26. Pribble CG, Black PG, Bosso JA, Turner RB. Clinical manifestations of exacerbations of cystic fibrosis associated with nonbacterial infections. J Pediatr 1990;117:200-204.
27. Emre U, Bernius M, Roblin PM, Gaerlan PF, Summersgill JT, Steiner P, Schachter J, Hammerschlag MR. Chlamydia pneumoniae infection in patients with cystic fibrosis. Clin Infect Dis 1996;22:819-823. (Pubitemid 26255601)
28. Clifton IJ, Kastelik JA, Peckham DG, Hale A, Denton M, Etherington C, Conway SP. Ten years of viral and non-bacterial serology in adults with cystic fibrosis. Epidemiol Infect 2008; 136:128-134.
29. Ong EL, Ellis ME, Webb AK, Neal KR, Dodd M, Caul EO, Burgess S. Infective respiratory exacerbations in young adults with cystic fibrosis: role of viruses and atypical microorganisms. Thorax 1989;44:739-742. (Pubitemid 19243272)
30. Miller MB, Gilligan PH. Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis. J Clin Microbiol 2003;41:4009-4015.
31. Sibley CD, Rabin H, Surette MG. Cystic fibrosis: a polymicrobial infectious disease. Future Microbiol 2006;1:53-61.
32. Bohte R, van Furth R, van den Broek PJ. Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital. Thorax 1995;50:543-547.
33. Endeman H, Schelfhout V, Voorn GP, Velzen-Blad H, Grutters JC, Biesma DH. Clinical features predicting failure of pathogen identification in patients with community acquired pneumonia. Scand J Infect Dis 2008;40:715-720.
34. Nair B, Stapp J, Stapp L, Bugni L, Van Dalfsen J, Burns JL. Utility of gram staining for evaluation of the quality of cystic fibrosis sputum samples. J Clin Microbiol 2002;40:2791-2794.
35. Tunney MM, Field TR, Moriarty TF, Patrick S, Doering G, Muhlebach MS, Wolfgang MC, Boucher R, Gilpin DF, McDowell A, Elborn JS. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 2008;177:995-1001.
36. Worlitzsch D, Rintelen C, Bohm K, Wollschlager B, Merkel N, Borneff-Lipp M, Doring G. Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients. Clin Microbiol Infect 2009;15:454-460.
37. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, Kehagia V, Connett GJ, Bruce KD. Use of 16S rRNA gene profiling by terminal restriction fragment length polymorphism analysis to compare bacterial communities in sputum and mouthwash samples from patients with cystic fibrosis. J Clin Microbiol 2006;44:2601-2604.
38. Harris JK, De Groote MA, Sagel SD, Zemanick ET, Kapsner R, Penvari C, Kaess H, Deterding RR, Accurso FJ, Pace NR. Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proc Natl Acad Sci USA 2007;104:20529-20533.
39. Sibley CD, Parkins MD, Rabin HR, Duan K, Norgaard JC, Surette MG. A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. Proc Natl Acad Sci USA 2008;105:15070-15075.
40. Olesen HV, Nielsen LP, Schiotz PO. Viral and atypical bacterial infections in the outpatient pediatric cystic fibrosis clinic. Pediatr Pulmonol 2006;41:1197-1204.
41. Ramsey BW, Wentz KR, Smith AL, Richardson M, Williams-Warren J, Hedges DL, Gibson R, Redding GJ, Lent K, Harris K. Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients. Am Rev Respir Dis 1991;144:331-337.
42. Rosenfeld M, Emerson J, Accurso F, Armstrong D, Castile R, Grimwood K, Hiatt P, McCoy K, McNamara S, Ramsey B, Wagener J. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1999;28:321-328.
43. Gutierrez JP, Grimwood K, Armstrong DS, Carlin JB, Carzino R, Olinsky A, Robertson CF, Phelan PD. Interlobar differences in bronchoalveolar lavage fluid from children with cystic fibrosis. Eur Respir J 2001;17:281-286.
44. Brennan S, Gangell C, Wainwright C, Sly PD. Disease surveillance using bronchoalveolar lavage. Paediatr Respir Rev 2008;9:151-159.